Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

NCT06918912 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma (HGBCL)
B-Cell Lymphoma Treatment
Relapsed or Refractory Lymphoma

Interventions

DRUG: Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)

Sponsor

Istituto Clinico Humanitas